News | October 02, 2007

Avid Holds Trial for Imaging Compound

October 3, 2007 - Avid Radiopharmaceuticals Inc., a product-focused molecular imaging company, announced today that enrollment has begun in a proof-of-concept phase I clinical trial investigating Avid’s development compound 18F-AV-133 for imaging patients with movement disorders, including Parkinson’s Disease (PD) and essential tremor and dementias, including Dementia with Lewy Bodies (DLB) and Alzheimer’s Disease (AD).

The compound, used with positron emission tomography (PET) imaging, targets vesicular monoamine transporters (VMAT2) in the brain and may enable more accurate and earlier diagnosis of neurodegenerative diseases. This new imaging compound may thus lead to improved disease management for patients and their caregivers. The study will be initially conducted at the University of Michigan and will involve 30 patients.

Avid’s 18F-AV-133 compound may also be useful for improved management of Alzheimer’s Disease (AD) because up to 25 percent of AD patients also have a component of PD or DLB. The goal of this initial trial is to determine whether 18F-AV-133 PET imaging can detect losses in nigrostriatal neurons in the brains of patients with AD, PD and DLB. Patients with overlapping symptoms and disease pathology are often misdiagnosed today.

The VMAT2 study represents the second clinical stage program in Avid’s development pipeline. The company, founded in 2004, is currently conducting a phase one clinical trial of its PET amyloid imaging compound for early detection of AD.

For more information: www.avidrp.com

Related Content

Voyageur Minerals to Begin Manufacturing Barium Contrast Products With Chief Medical Supply
News | Contrast Media | November 14, 2018
Voyageur Minerals Ltd. signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta to...
Osprey Medical and GE Healthcare Launch Acute Kidney Injury Educational Program
News | Angiography | September 25, 2018
September 21, 2018 — Osprey Medical announced a collaboration with GE Healthcare on Osprey’s Be Kind to Kidneys campa
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Scientists Develop New MRI Tool for Cancer Diagnosis and Therapy

Researchers in the laboratory ‘Biomedical Nanomaterials’ of NUST MISIS. Image courtesy of PR Newsfoto/NUST MISIS.

News | Oncology Diagnostics | August 24, 2018
A European research group has developed a system that allows doctors to both improve the accuracy of diagnosing...
Iron Outperforms Gadolinium as MRI Contrast Agent

Scientists at Rice's Laboratory for Nanophotonics added iron chelates (blue) and fluorescent dye (red) to multi-layered gold nanomatryoshkas to create particles that can be used for disease therapy and diagnostics. The "theranostic" nanoparticles have a core of gold (left) that is covered by silica containing the diagnostic iron and dye, which is covered by an outer shell of gold. The particles are about 20 times smaller than a red blood cell, and by varying the thickness of the layers, LANP scientists can tune the nanomatryoshkas to convert light into cancer-killing heat. (Image courtesy of Luke Henderson/Rice University)

News | Contrast Media | August 22, 2018
Rice University nanoscientists have demonstrated a method for loading iron inside nanoparticles to create magnetic...
Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence
News | Radiation Dose Management | August 14, 2018
August 14, 2018 — Guerbet LLC USA announced a commercial partnership with Imalogix, a provider of...
Videos | Contrast Media | August 03, 2018
Lawrence Tanenbaum, M.D., FACR, vice president and director of advanced imaging at RadNet, discusses the latest resea
Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018
Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...